Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05364255 | A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 | PHASE1 | COMPLETED | 6 | — | — | May 10, 2022 | Jun 20, 2022 | Jun 21, 2024 | 1 | United Kingdom |
Assessment of the total radioactivity by measuring the cumulative amount of AZD9833 excreted
Assessment of the total radioactivity, expressed as a percentage, by measuring the cumulative amount of AZD9833 excreted
| Arm | Type | Description |
|---|---|---|
| [14C]AZD9833 (D8532C00005) | EXPERIMENTAL | Oral Solution, 75 mg (NMT 0.67 MBq) |
| Name | Type | Description |
|---|---|---|
| [14C]AZD9833 Oral Solution, 75 mg | DRUG | Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Aged between 50 to 70 years inclusive at the time of signing informed consent * Healthy post-menopausal females, defined as post-menopausal by fulfilling the following criterion: ...